{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:38:02Z","timestamp":1786977482548,"version":"build-2736575974"},"reference-count":46,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:p>\n                    Disease trajectories following antibody therapy can have a significant impact on the pharmacokinetics of the antibody. Although this phenomenon can often be explained by reduced target\u2010expressing cells, other mechanisms may play a role. We use a novel minimal physiologically\u2010based pharmacokinetic model to evaluate an alternative drug\u2013disease interaction mechanism involving competitive inhibition of neonatal Fc receptor (FcRn)\u2010mediated Immunoglobulin G recycling by paraproteins. The model is validated with clinical data from the anti\u2010FcRn antibody M281 and is used to conduct a scenario test to quantify the interaction among M\u2010protein, the characteristic paraprotein of multiple myeloma (\n                    <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>\n                    ), and the anti\u2010\n                    <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>\n                    38 antibody daratumumab indicated for\n                    <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>\n                    treatment. Simulations predict up to a 3.6\u2010fold increase in daratumumab half\u2010life following M\u2010protein reduction, which lends credence to the hypothesis that FcRn competition in\n                    <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>\n                    can manifest as time\u2010dependent reduction of clearance for daratumumab. This model can inform optimal dosing strategies for antibodies in\n                    <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>\n                    and other pathologies of paraprotein excess.\n                  <\/jats:p>","DOI":"10.1002\/cpt.1619","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T15:10:08Z","timestamp":1566832208000},"page":"423-434","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Minimal Physiologically\u2010Based Pharmacokinetic Model Demonstrates Role of the Neonatal Fc Receptor (FcRn) Competition in Drug\u2013Disease Interactions With Antibody Therapy"],"prefix":"10.1111","volume":"107","author":[{"given":"Hussein M.","family":"Abdallah","sequence":"first","affiliation":[{"name":"Takeda Pharmaceutical Company Limited Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy Z.X.","family":"Zhu","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"key":"e_1_2_10_1_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574884712666170809124728"},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2014.925878"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2012.643868"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.170"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.134"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000437077"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02914.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802475303"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00190.x"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199683307.001.0001"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.665"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1276"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.959-962.2005"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0477-1"},{"key":"e_1_2_10_19_1","unstructured":"Marilyn Kehry D.J.K. Ling L.E. Meador III J. Roy S.&Manning A.FcRn antibodies and methods of use thereof. C07K 16\/28 (2006.01) G01N 33\/68 (2006.01) A61K 49\/00 (2006.01) edn. (Momenta Pharmaceuticals Inc. 2016)."},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60665-5"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07547.x"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-013-9332-2"},{"key":"e_1_2_10_23_1","volume-title":"Population pharmacokinetics and exposure\u2010response analyses to support dose selection of daratumumab in multiple myeloma patients","author":"Marchand M.","year":"2013"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.4861.4861"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00626"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.065920"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2016.04.004"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-011-9232-2"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-014-9372-2"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-012-9280-2"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.03.009"},{"key":"e_1_2_10_32_1","unstructured":"Janssen Pharmaceuticals. Darzalex (daratumumab) product information"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-705210"},{"key":"e_1_2_10_34_1","first-page":"682","article-title":"Unraveling the interaction between FcRn and albumin: opportunities for design of albumin\u2010based therapeutics","volume":"5","author":"Sand K.M.","year":"2014","journal-title":"Front. Immunol."},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi052628y"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2006.05.004"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1159\/000090185"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc11218"},{"key":"e_1_2_10_39_1","first-page":"426","article-title":"Analysis of serum protein changes in patients with advanced gastric cancer with special reference to \u03b1\u2010globulin fractions","volume":"32","author":"Shoji Suga Z.T.","year":"1972","journal-title":"Cancer Res."},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840160320"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.4240\/wjgs.v7.i12.370"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-9-69"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-016-9482-0"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1403014"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.5.3266"},{"key":"e_1_2_10_46_1","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.157.2.950","article-title":"Human IgG production in vivo: determination of synthetic rate by nonradioactive tracer incorporation","volume":"157","author":"Thornton C.A.","year":"1996","journal-title":"J. Immunol."}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1619","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.1619","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T08:31:42Z","timestamp":1699345902000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.1619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,25]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1002\/cpt.1619"],"URL":"https:\/\/doi.org\/10.1002\/cpt.1619","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,25]]},"assertion":[{"value":"2019-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}